When intravenously treated with a cocktail of B. bifidum, B. longum, B. lactis, and B. breve in tandem with an anti-CD47 immunotherapy in mouse models of colon adenocarcinoma (MC38) and T cell lymphoma (EG7) cell lines, Bifidobacterium localized within the tumor environment and utilized the STING (stimulator interferon genes) pathway to regulate type I IFN signaling. This evidence concerns the gene STING1 and T-cell non-Hodgkin lymphoma.